Chembio Diagnostics Inc (CEMI) Shares Bought by Benchmark Capital Advisors

Benchmark Capital Advisors raised its holdings in shares of Chembio Diagnostics Inc (NASDAQ:CEMI) by 101.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 66,417 shares of the company’s stock after buying an additional 33,517 shares during the quarter. Benchmark Capital Advisors’ holdings in Chembio Diagnostics were worth $545,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Goldman Sachs Group Inc. acquired a new stake in Chembio Diagnostics during the 2nd quarter valued at approximately $151,000. 33.96% of the stock is currently owned by institutional investors and hedge funds.

Shares of Chembio Diagnostics Inc (NASDAQ:CEMI) opened at $7.75 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.19 and a current ratio of 3.54. Chembio Diagnostics Inc has a 12 month low of $5.05 and a 12 month high of $9.20. The company has a market cap of $95.59, a P/E ratio of -13.60 and a beta of 1.14.

Chembio Diagnostics (NASDAQ:CEMI) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.06. Chembio Diagnostics had a negative net margin of 32.42% and a negative return on equity of 42.76%. The business had revenue of $7.59 million during the quarter, compared to analysts’ expectations of $5.65 million. equities research analysts predict that Chembio Diagnostics Inc will post -0.48 earnings per share for the current year.

WARNING: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2018/02/09/chembio-diagnostics-inc-cemi-shares-bought-by-benchmark-capital-advisors.html.

About Chembio Diagnostics

Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.

Want to see what other hedge funds are holding CEMI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chembio Diagnostics Inc (NASDAQ:CEMI).

Institutional Ownership by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply